OmniAb to Report Fourth Quarter 2024 Financial Results on March 18
OmniAb (NASDAQ: OABI) will announce its fourth quarter and full-year 2024 financial results on March 18, 2025, after the U.S. financial markets close. The company will also hold a conference call on the same day at 4:30 p.m. Eastern time to discuss the results.
OmniAb (NASDAQ: OABI) annuncerà i suoi risultati finanziari del quarto trimestre e del bilancio annuale 2024 il 18 marzo 2025, dopo la chiusura dei mercati finanziari statunitensi. L'azienda terrà anche una conference call lo stesso giorno alle 16:30 ora orientale per discutere i risultati.
OmniAb (NASDAQ: OABI) anunciará sus resultados financieros del cuarto trimestre y del año fiscal 2024 el 18 de marzo de 2025, después del cierre de los mercados financieros de EE. UU. La compañía también realizará una llamada de conferencia el mismo día a las 4:30 p.m. hora del Este para discutir los resultados.
OmniAb (NASDAQ: OABI)는 2025년 3월 18일, 미국 금융 시장이 마감된 후 2024년 4분기 및 연간 재무 결과를 발표할 예정입니다. 회사는 같은 날 동부 표준시 기준 오후 4시 30분에 컨퍼런스 콜을 개최하여 결과를 논의할 것입니다.
OmniAb (NASDAQ: OABI) annoncera ses résultats financiers du quatrième trimestre et de l'année 2024 le 18 mars 2025, après la fermeture des marchés financiers américains. La société tiendra également une conférence téléphonique le même jour à 16h30, heure de l'Est, pour discuter des résultats.
OmniAb (NASDAQ: OABI) wird am 18. März 2025 nach Schließung der US-Finanzmärkte seine Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 bekannt geben. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time auch eine Konferenzschaltung abhalten, um die Ergebnisse zu besprechen.
- None.
- None.
Conference Call and Webcast Information
What: |
|
OmniAb conference call to discuss fourth quarter financial results and business updates |
|
|
|
Date: |
|
Tuesday, March 18, 2025 |
|
|
|
Time: |
|
4:30 p.m. Eastern time (1:30 p.m. Pacific time) |
|
|
|
Phone: |
|
|
|
|
International (289) 819 1520 |
|
|
Conference ID is 84579 |
|
|
|
Webcast: |
|
Live and replay webcast of the call with slides will be available here. |
About OmniAb®
OmniAb licenses cutting edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is something we call Biological Intelligence™, which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, is used to identify fully-human antibodies with exceptional performance and developability characteristics. We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized discovery solutions. Our business model aligns scientific and economic interests of our partners through structured agreements that generally include upfront/access fees, service revenue, milestones and royalties on commercial sales.
For more information, please visit www.omniab.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250224108779/en/
OmniAb, Inc.
Neha Singh, Ph.D.
investors@OmniAb.com
X @OmniAbTech
(510) 768-7760
Source: OmniAb, Inc.
FAQ
When will OmniAb report its Q4 2024 financial results?
What time is the OmniAb Q4 2024 earnings conference call?
Where can I find OmniAb's Q4 2024 financial results?
What is the stock symbol for OmniAb?
